Laurion Capital Management’s Immunocore IMCR Stock Holding History

Laurion Capital Management’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-53,332	Closed	-$3.47M	–	645
2024 Q1	$3.47M	Buy	+53,332	New	+$3.66M	0.03%	290
2021 Q2	–	Sell	-5,000	Closed	-$213K	–	812
2021 Q1	$213K	Buy	+5,000	New	+$223K	﹤0.01%	690

Other funds holding IMCR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Laurion Capital Management's IMCR Position: Q2 2024 in Review

Laurion Capital Management sold out of Immunocore (IMCR) in Q2 2024, closing a stake of 53,332 shares — an estimated $3.47M sold.

Laurion Capital Management first reported a position in IMCR in Q1 2021 and held it in 2 quarters. The position peaked at $3.47M in Q1 2024. 138 funds tracked by Wall St. Rank hold IMCR as of Q2 2024.

Laurion Capital Management reported no remaining Immunocore position as of Q2 2024 after selling out during the quarter.
Laurion Capital Management sold 53,332 Immunocore shares in Q2 2024, an estimated $3.47M.
Laurion Capital Management first reported a position in Immunocore in Q1 2021 and held it in 2 quarters.
Laurion Capital Management's Immunocore position peaked at $3.47M in Q1 2024.
138 funds tracked by Wall St. Rank held Immunocore as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.